Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration.
Miroslava Rohanová, Tomáš Páleníček, Marie Balíková
Toxicology Letters April 21, 2008 DOI: 10.1016/j.toxlet.2008.01.017 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | 2C-B |
| Duration | 6 hours after the dose |
| Keywords | 2c-b Psychedelic compound Original compound Pharmacokinetics Drug distribution Absorption Concentrations Half-life Processing Entered the brain Lung retention Efficiency Drug metabolism Major metabolite Neuropharmacology Brain tissue Brain entry Understanding its effects |
| Citations | 33 |
| Key findings | 2C-B rapidly enters the brain after subcutaneous administration in rats, with a half-life of 1.1 hours and a brain-to-serum ratio that peaks at 13.9 and remains elevated for at least six hours. |
Abstract
The psychedelic compound 4-bromo-2,5-dimethoxyphenethylamine (2C-B) has appeared as an agent in drug abuse or overdose cases in humans. The human pharmacokinetics of this drug is unknown and only partial information is available on its metabolites. Our experimental study was focused on the disposition and kinetic profile of 2C-B in rats after subcutaneous administration using a GC-MS validated method. One of the major metabolites 4-bromo-2-hydroxy-5-methoxyphenethylamine (2H5M-BPEA) was confirmed in rat tissues of lung, brain, liver and was quantitatively evaluated as well. The disposition of 2C-B was characterized by its estimated half-life 1.1h and estimated volume of distribution 16L/kg. The lung susceptibility for drug retention and gradual temporal release parallel to the brain were ascertained. The drug penetrating the blood/brain barrier was without significant delay. 2C-B brain to serum ratio attained a maximum value of 13.9 and remained over the value of 6.5 to the end of our observation (6h after the dose). The distribution of the hydroxylated metabolite 2H5M-BPEA into the lipophilic brain tissue was less efficient in relation to the parent compound. The kinetics of the drug partitioning between blood to brain may be important for the subsequent assessment of its psychotropic or toxic effects.
Citations in the library
Cited by 17
- Clinical toxicology of newer recreational drugs Clinical Toxicology October 1, 2011
- 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal of Psychopharmacology July 1, 2012
- Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? Pharmacology & Therapeutics February 1, 2018
- Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicology in Vitro December 1, 2017
- Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo Scientific Reports October 3, 2019
and 12 more in the library
Cites 9
- Dihydrobenzofuran Analogues of Hallucinogens. 3. Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigidified Methoxy Groups Journal of Medicinal Chemistry 1996
- A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharmacy world & science : PWS April 1, 2004
- Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology January 5, 2005
- 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. Journal of Analytical Toxicology September 1, 1998
- 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. British Journal of Pharmacology April 1, 2004
and 4 more in the library